Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Samantha Jaglowski, et al.
In the real-world, tisa-cel has similar efficacy and improved safety in DLBCL patients. OOS product (viability 60-80%) does not impact efficacy
